(Stroke. 1999;30:2038-2042.)
© 1999 American Heart Association, Inc.
Original Contributions |
Safety and Tolerability Study of Aptiganel Hydrochloride in Patients With an Acute Ischemic Stroke
From Acute Stroke Unit, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK (A.G.D., K.R.L.); Southwestern Vermont Medical Center, Bennington, Vt (K.R.E.); Yale University School of Medicine, Department of Neurology, New Haven, Conn (P.B.F.); and Marietta Neurologic Associates, Marietta, Ga (J.T.H.).
Correspondence to Dr A.G. Dyker, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK. E-mail ad47q{at}clinmed.gla.ac.uk
Background and Purpose—Aptiganel (CNS 1102) is a selective, noncompetitive antagonist that acts on the ion channel associated with the N-methyl-D-aspartate (NMDA) receptor and is neuroprotective in experimental focal cerebral ischemia models at a plasma concentration of 10 ng/mL. In human volunteers, dose-limiting effects of aptiganel are blood pressure increases and central nervous system (CNS) excitation or depression. This study assessed the safety and tolerability of non–weight-adjusted doses of aptiganel in patients with acute ischemic stroke.
Methods—This was a double-blind, randomized, placebo-controlled multicenter study in patients presenting within 24 hours of acute ischemic stroke. Ascending single intravenous bolus doses of aptiganel (3, 4.5, 6, and 7.5 mg) were assessed in 21 patients with a 3:1 active drug:placebo randomization schedule. In 15 subsequent patients, selected bolus doses were followed by constant intravenous infusion for 6 to 12 hours (6 mg plus 1 mg/h, n=10; then 4.5 mg plus 0.75 mg/h, n=15) in a 4:1 randomization schedule. Prospectively collected pharmacokinetic data guided selection of infusion rates. Neurological and functional status were recorded at entry and after 1 week, although the study was not designed to test efficacy.
Results—Forty-six patients were randomized from 4 centers (3 in
the United States and 1 in the United Kingdom): 36 received aptiganel
HCl, and 10 were given placebo. Hypertension and CNS events were
commonly reported after a bolus dose of 7.5 mg and after a 6-mg bolus
followed by an infusion of 1 mg/h. The lower regimen of 4.5-mg bolus
followed by infusion of 0.75 mg/h achieved plasma aptiganel
concentrations of >10 ng/mL and was well tolerated by patients but
still raised systolic blood pressure by 
30 mm Hg over
baseline.
Conclusions—A 4.5-mg intravenous bolus of aptiganel HCl followed by infusion of 0.75 mg/h for 12 hours is a tolerable dose that can produce plasma drug concentrations shown to be neuroprotective in animal models. However, increases in systolic blood pressure and an excess of CNS effects were both observed at this dose.
Key Words: aptiganel • stroke, acute • neuroprotection • glutamate antagonists • NMDA antagonists
This article has been cited by other articles:
 |
|
 |
|
  S. Papadia and G. E. Hardingham The Dichotomy of NMDA Receptor Signaling Neuroscientist, December 1, 2007; 13(6): 572 - 579. [Abstract] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Danton and W. D. Dietrich The Search for Neuroprotective Strategies in Stroke AJNR Am. J. Neuroradiol., February 1, 2004; 25(2): 181 - 194. [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Albers, L. B. Goldstein, D. Hall, L. M. Lesko, and for the Aptiganel Acute Stroke Investigators Aptiganel Hydrochloride in Acute Ischemic Stroke: A Randomized Controlled Trial JAMA, December 5, 2001; 286(21): 2673 - 2682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lees, A. G. Dyker, A. Sharma, G. A. Ford, M. E. Ardron, and D. G. Grosset Tolerability of the Low-Affinity, Use-Dependent NMDA Antagonist AR-R15896AR in Stroke Patients : A Dose-Ranging Study Stroke, February 1, 2001; 32(2): 466 - 472. [Abstract] [Full Text] [PDF]
|
|